NAV

Allogeneic Cardiosphere-Derived Cells

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Allogeneic Cardiosphere-Derived Cells
DrugBank Accession Number
DB15744
Background

Cardiosphere-derived cells (CDCs) are derived from human neonatal heart tissue with a distinct antigenic profile (CD105+, CD45-, and CD90low). They exert their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of cell-cell communication. CDCs target multiple cytokine pathways associated with poor outcomes (e.g. TNFa, IFN-y, IL-1B, and IL-15). The anti-inflammatory effects of CDC work through polarizing macrophages and restoring tissue function.

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
Not Available
External IDs
  • CAP-1002
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Cardiosphere-derived cell exosomes can reduce cardiac scar size, improve myocardial function, and attenuate damaging remodeling that occurs from infections. CAP-1002 was formulated as an intravenous infusion of cardiosphere-derived cells and is currently being investigated as a treatment for critically ill COVID-19 patients.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
ZM7OCV7H6H
CAS number
Not Available

References

General References
  1. Chakravarty T, Makkar RR, Ascheim DD, Traverse JH, Schatz R, DeMaria A, Francis GS, Povsic TJ, Smith RR, Lima JA, Pogoda JM, Marban L, Henry TD: ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: Rationale and Design. Cell Transplant. 2017 Feb 16;26(2):205-214. doi: 10.3727/096368916X692933. Epub 2016 Aug 18. [Article]
  2. Taylor M, Jefferies J, Byrne B, Lima J, Ambale-Venkatesh B, Ostovaneh MR, Makkar R, Goldstein B, Smith RR, Fudge J, Malliaras K, Fedor B, Rudy J, Pogoda JM, Marban L, Ascheim DD, Marban E, Victor RG: Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial. Neurology. 2019 Feb 19;92(8):e866-e878. doi: 10.1212/WNL.0000000000006950. Epub 2019 Jan 23. [Article]
  3. Singh S, Chakravarty T, Chen P, Akhmerov A, Falk J, Friedman O, Zaman T, Ebinger JE, Gheorghiu M, Marban L, Marban E, Makkar RR: Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series. Basic Res Cardiol. 2020 May 12;115(4):36. doi: 10.1007/s00395-020-0795-1. [Article]
  4. Kapelios CJ, Nanas JN, Malliaras K: Allogeneic cardiosphere-derived cells for myocardial regeneration: current progress and recent results. Future Cardiol. 2016 Jan;12(1):87-100. doi: 10.2217/fca.15.72. Epub 2015 Dec 21. [Article]
  5. Saha P, Sharma S, Korutla L, Datla SR, Shoja-Taheri F, Mishra R, Bigham GE, Sarkar M, Morales D, Bittle G, Gunasekaran M, Ambastha C, Arfat MY, Li D, Habertheuer A, Hu R, Platt MO, Yang P, Davis ME, Vallabhajosyula P, Kaushal S: Circulating exosomes derived from transplanted progenitor cells aid the functional recovery of ischemic myocardium. Sci Transl Med. 2019 May 22;11(493). pii: 11/493/eaau1168. doi: 10.1126/scitranslmed.aau1168. [Article]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentDiseases of the Nervous System / Duchenne Muscular Dystrophy (DMD) / Genetic Diseases, Inborn / Muscular Disorders, Atrophic / Musculoskeletal Disorders / Neuromuscular Disorders / X-linked chromosomal disorder1
2Active Not RecruitingTreatmentDuchenne Muscular Dystrophy (DMD)1
2CompletedTreatmentCongestive Heart Failure (CHF) / Heart Failure, Diastolic1
2CompletedTreatmentCoronavirus Disease 2019 (COVID‑19)1
2CompletedTreatmentDiseases of the Nervous System / Duchenne Muscular Dystrophy (DMD) / Genetic Diseases, Inborn / Muscular Disorders, Atrophic / Musculoskeletal Disorders / Neuromuscular Disorders / X-linked chromosomal disorder1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at August 11, 2020 21:15 / Updated at June 02, 2023 02:07